Novel approaches to antiviral and anticancer immunotherapy

Acta Virologica

Volumn 56, Issue 4, 2012, Pages 271-282

  Trnkova K ^a   Pastorekova S ^a   Petrik, J ^a,b  

^a INSTITUTE OF VIROLOGY   (Slovakia)

^b SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

Author keywords

Anti measles immunity; Bi functional protein; Re directed immunotherapy

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CANCER VACCINE; CD134 ANTIGEN; CD40 LIGAND; CETUXIMAB; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FLAGELLIN; G 207; GEMTUZUMAB OZOGAMICIN; INTERFERON; LIPOPOLYSACCHARIDE; LONTUCIREV; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; NV 1020; PALIVIZUMAB; RIBAVIRIN; RITUXIMAB; SECONDARY LYMPHOID TISSUE CHEMOKINE; TOLL LIKE RECEPTOR 3; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNINDEXED DRUG; VEDOTIN;

ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DRUG MEGADOSE; GLIOBLASTOMA; HAIRY CELL LEUKEMIA; HEAD AND NECK CANCER; HEPATITIS B; HEPATITIS C; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LARGE CELL LYMPHOMA; LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; RNA SEQUENCE; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; VIRUS INFECTION;

ANIMALS; ANTIGENS, NEOPLASM; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; VIRUS DISEASES;

EID: 84873734027     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: 10.4149/av_2012_04_271     Document Type: Article

References (62)

1. Akira S, Uematsu S, Takeuchi O (2006): Pathogen recognition and innate immunity. Cell 124, 783-801. http://dx.doi.org/10.1016/j.cell.2006.02.015
2. Andersen H, Barsov EV, Trivett MT, Trubey CM, Giavedoni LD, Lifson JD, Ott DE, Ohlen C (2007): Transduction with human telomerase reverse transcriptase immortalizes a rhesus macaque CD8+ T cell clone with maintenance of surface marker phenotype and function. AIDS Res. Hum. Retroviruses 23, 456-465. http://dx.doi.org/10.1089/aid.2006.0194
3. Barsov E (2011): Telomerase and primary T cells: biology and immortalization for adoptive immunotherapy. Immunotherapy 3, 407-421. http://dx.doi.org/10.2217/imt.10.107
4. Biagi E, Marin V, Attianese GMPG, Pizzitola I, Tettamanti S, Cribioli E, Biondi A (2011): New advances in leukemia immunotherapy by the use of chimeric artificial antigen receptors (CARs): state of the art and perspectives for the near future. Ital. J. Pediatr. 37, 46. http://dx.doi.org/10.1186/1824-7288-37-46
5. Chen W (2011): Tregs in immunotherapy: opportunities and challenges. Immunotherapy 3, 911-914. http://dx.doi.org/10.2217/imt.11.79
6. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004): Discovery and development of Bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391-400. http://dx.doi.org/10.1038/nrd1381
7. Fournier P, Brons NH, Berbers GA, Wiesmuller KH, Fleckenstein BT, Schneider F, Jung G, Muller CP (1997): Antibodies to a new linear site at the topographical or functional interface between the haemagglutinin and fusion proteins protect against measles encephalitis. J. Gen. Virol. 78, 1295-1302.
8. Gibbert K, Dittmer U (2011): Distinct antiviral activities of IFN-a subtypes. Immunotherapy 3, 813-816. http://dx.doi.org/10.2217/imt.11.74
9. Gough MJ, Weinberg AD (2009): OX40 (CD134) and OX40L. Adv. Exp. Med. Biol. 647, 94-107. http://dx.doi.org/10.1007/978-0-387-89520-8_6
10. Goulding J, Tahiliani V, Salek-Ardakani S (2011): OX40:OX40L axis: emerging targets for improving poxvirus-based CD8(+) T-cell vaccines against respiratory viruses. Immunol. Rev. 244, 149-168. http://dx.doi.org/10.1111/j.1600-065X.2011.01062.x
11. Harrington KJ, Hingorani M, Tanay MA, Hickey J, Bhide SA, Clarke PM, Renouf LC, Thway K, Sibtain A, McNeish IA, Newbold KL, Goldsweig H, Coffin R, Nutting CM (2010): Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin. Cancer Res. 16, 4005-15. http://dx.doi.org/10.1158/1078-0432.CCR-10-0196
12. Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ (1994): Comparative analysis of B7-1 and B7-2 co-stimulatory ligands: expression and function. J. Exp. Med. 180, 631-640. http://dx.doi.org/10.1084/jem.180.2.631
13. Hudis CA (2007): Trastuzumab - mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39-51. http://dx.doi.org/10.1056/NEJMra043186
14. Hummel KB, Bellini WJ (1995): Localization of monoclonal antibody epitopes and functional domains in the hemagglutinin protein of measles virus. J. Virol. 69, 1913-1916.
15. Jaks E, Gavutis M, Uze G, Martal J, Piehler J (2007): Differential receptor subunits affinities of type I interferons govern differential signal activations. J. Mol. Biol. 366, 525-539. http://dx.doi.org/10.1016/j.jmb.2006.11.053
16. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986): Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522-525. http://dx.doi.org/10.1038/321522a0
17. Kaneko Y, Nimmerjahn F, Ravetch JV (2006): Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 31, 3670-673.
18. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR (2010a): Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28, 1099-1105. http://dx.doi.org/10.1200/JCO.2009.25.0597
19. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators (2010b): Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422. http://dx.doi.org/10.1056/NEJMoa1001294
20. Kelly E, Russell SJ (2007): History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 15, 651-659.
21. King J, Waxman J, Stauss H (2008): Advances in tumor immunotherapy. J. Med. 101, 675-683.
22. Kohler G, Milstein C (1975): Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497. http://dx.doi.org/10.1038/256495a0
23. Law M, Hangartner L (2008): Antibodies against viruses: passive and active immunization. Curr. Opin. Immunol. 20, 486-492. http://dx.doi.org/10.1016/j.coi.2008.06.005
24. Lechner MG, Russell SM, Bass RS, Epstein AL (2011): Chemokines, co-stimulatory molecules and fusion proteins in the immunotherapy of solid tumors. Immunotherapy 3, 1317-1340. http://dx.doi.org/10.2217/imt.11.115
25. Lecouturier V, Fayolle J, Caballero M, Carabana J, Celma ML, Fernandez-Munoz R, Wild TF, Buckland R (1996): Identification of two amino acids in the hemagglutinin glycoprotein of measles virus (MV) that govern hemadsorption, HeLa cell fusion, and CD46 downregulation: phenotypic markers that differentiate vaccine and wildtype MV strains. J. Virol. 70, 4200-4204.
26. Leen AM, Heslop HE (2008): Cytotoxic T lymphocytes as immune-therapy in haematological practice. Br. J. Haematol. 143, 169-179. http://dx.doi.org/10.1111/j.1365-2141.2008.07316.x
27. Leen AM, Tripic T, Rooney CM (2010): Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert. Opin. Biol. Ther. 10, 337. http://dx.doi.org/10.1517/14712590903456003
28. Lin CW, Lee JY, Tsao YP, Shen CP, Lai HC, Chen SL (2002): Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 and E7 can cause tumor growth in miceto regress. Int. J. Cancer 102, 629-637. http://dx.doi.org/10.1002/ijc.10759
29. Lu PH, Negrin RS (1994): A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J. Immunol. 153, 1687-1696.
30. Lugthart G, Albon SJ, Ricciardelli I, Kester MGD, Meij P, Lankester AC, Amrolia PJ (2012): Simultaneous generation of multivirus-specific and regulatory T-cells for adoptive immunotherapy. J. Immunother. 35, 42-53. http://dx.doi.org/10.1097/CJI.0b013e31823569e2
31. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM (1991): Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854-856. http://dx.doi.org/10.1126/science.1851332
32. Masood A, Sher T, Paulus A, Miller KC, Chitta KS, Chanan-Khan A (2011): Targeted treatment for chronic lymphocytic leukemia. OncoTargets Ther. 4, 169-183.
33. McCafferty J, Griffith AD, Winter G, Chiswell DJ (1990): Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552-554. http://dx.doi.org/10.1038/348552a0
34. Meerani S, Yao Y (2010): Oncolytic viruses in cancer therapy. Eur. J. Sci. Res. 40, 156-171.
35. Mellman I, Coukos G, Dranoff G (2011): Cancer immunotherapy comes of age. Nature 480, 480-489. http://dx.doi.org/10.1038/nature10673
36. Monie A, Tsen S-WD, Hung C-F, Wu T-C (2009): Therapeutic HPV DNA vaccines. Expert Rev. Vaccines 8, 1221-1235. http://dx.doi.org/10.1586/erv.09.76
37. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, De Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA (2006): Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129. http://dx.doi.org/10.1126/science.1129003
38. Morse MA, Chapman R, Powderly J, Blackwell K, Keler T, Green J, Riggs R, He LZ, Ramakrishna V, Vitale L, Zhao B, Butler SA, Hobeika A, Osada T, Davis T, Clay T, Lyerly HK (2011): Phase I study utilizing a novel antigenpresenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin. Cancer Res. 17, 4844-4853. http://dx.doi.org/10.1158/1078-0432.CCR-11-0891
39. Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P, Iacone A (2009): Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumors: a pilot clinical trial. Hematol. Oncol. 27, 130-139. http://dx.doi.org/10.1002/hon.886
40. Pastorekova S, Parkkila, S, Zavada J (2006): Tumor-associated carbonic anhydrases and their clinical significance. Adv. Clin. Chem. 42, 167-216. http://dx.doi.org/10.1016/S0065-2423(06)42005-9
41. Pastorekova S, Ratcliffe PJ, Pastorek J (2008): Molecular mechanisms of carbonic anhydrase IX-mediated pH regulation under hypoxia. BJU Int. 4, 8-15. http://dx.doi.org/10.1111/j.1464-410X.2008.07642.x
42. Pescowitz MD (2006): Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am. J. Transplant. 6, 859-866. http://dx.doi.org/10.1111/j.1600-6143.2006.01288.x
43. Petrik J (2001): Recombinant therapeutic fusion proteins. WO 01/32893 A1.
44. Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, Fremont DH, Diamond MS (2007): The stoichiometry of antibodymediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1, 135-145. http://dx.doi.org/10.1016/j.chom.2007.03.002
45. Pollack P, Groothuis JR (2002): Development and use of Palivizumab (Synagis): a passive immunoprophylactic agent for RSV. J. Infect. Chemother. 8, 201-206. http://dx.doi.org/10.1007/s10156-002-0178-6
46. Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F (2008): Oncolytic viruses: a novel form of immunotherapy. Expert Rev. Anticancer Ther. 8, 1581-1588. http://dx.doi.org/10.1586/14737140.8.10.1581
47. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK (2008): Virus specific T cells engineered to co-express tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14, 1264-1270. http://dx.doi.org/10.1038/nm.1882
48. Reichert JM (2011): Antibody-based therapeutics to watch in 2011. MAbs 3, 76-99. http://dx.doi.org/10.4161/mabs.3.1.13895
49. Rudin CM, Cohen EE, Papadimitrakopoulou VA, Silverman S Jr, Recant W, El-Naggar AK, Stenson K, Lippman SM, Hong WK, Vokes EE (2003): An attenuated adenovirus, ONYX- 015, as mouthwash therapy for premalignant oral dysplasia. J. Clin. Oncol. 21, 4546-4552. http://dx.doi.org/10.1200/JCO.2003.03.544
50. Sangiolo D (2011): Cytokine induced killer cells as promising immunotherapy for solid tumors. J. Cancer 2, 363-368. http://dx.doi.org/10.7150/jca.2.363
51. Sato TA, Enami M, Kohama T (1995): Isolation of the measles virus hemagglutinin protein in a soluble form by protease digestion. J. Virol. 69, 513-516.
52. Schmitt TM, Ragnarsson GB, Greenberg PD (2009): T cell receptor gene therapy for cancer. Human Gene Therapy 20, 1240-1248. http://dx.doi.org/10.1089/hum.2009.146
53. Stewart TJ, Smyth MJ (2009): Chemokine-chemokine receptors in cancer immunotherapy. Immunotherapy. 1, 109-127. http://dx.doi.org/10.2217/1750743X.1.1.109
54. Thomas S, Stauss HJ, Morris EC (2010): Molecular immunology lessons from therapeutic T cell receptor gene transfer. Immunology 129, 170-177. http://dx.doi.org/10.1111/j.1365-2567.2009.03227.x
55. Tse K, Horner AA (2007): Update on toll-like receptor-directed therapies for human disease. Ann. Rheum. Dis. 66 (Suppl. III), iii77-80. http://dx.doi.org/10.1136/ard.2007.078998
56. Verra NC, Jorritsma A, Weijer K, Ruizendaal JJ, Voordouw A, Weder P, Hooijberg E, Schumacher TN, Haanen JB, Spits H, Luiten RM (2004): Human telomerase reverse transcriptasetransduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice. Cancer Res. 64, 2153-2161. http://dx.doi.org/10.1158/0008-5472.CAN-03-1339
57. Wennier S, Li S, McFadden G (2011): Oncolytic virotherapy for pancreatic cancer. Expert Rev. Mol. Med. 13, e18. http://dx.doi.org/10.1017/S1462399411001876
58. Yamada T (2011): Therapeutic monoclonal antibodies. Keio J. Med. 60, 37-46. http://dx.doi.org/10.2302/kjm.60.37
59. Yang X, Kurteva S, Lee S, Sodroski J (2005): Stoichiometry of antibody neutralization of human immunodeficiency virus type 1. J. Virol. 79, 3500-3508. http://dx.doi.org/10.1128/JVI.79.6.3500-3508.2005
60. Zavada J, Zavadova Z, Pastorek J, Biesova Z, Jezek J, Velek J (2000): Human tumorassociated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br. J. Cancer 82, 1808-1813 http://dx.doi.org/10.1054/bjoc.2000.1111
61. Zatovicova M, Tarabkova K, Svastova E, Gibadulinova A, Mucha V, Jakubickova L, Biesova Z, Rafajova M, Ortova Gut M, Parkkila S, Parkkila AK, Waheed A, Sly WS, Horak I, Pastorek J, Pastorekova S (2003): Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumor-associated hypoxia-induced carbonic anhydrase IX. J. Immunol. Methods 282, 117-134. http://dx.doi.org/10.1016/j.jim.2003.08.011
62. Zatovicova M, Jelenska L, Hulikova A, Csaderova L, Ditte Z, Ditte P, Goliasova T, Pastorek J, Pastorekova S (2010): Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr. Pharm. Des. 16, 3255-3263. http://dx.doi.org/10.2174/13816121079342983